LUNGevity Foundation engages with many public policy issues but focuses on areas that pertain to the advancement of innovation and access to care.
We present at Capitol Hill briefings, submit letters to legislators, regulators, and independent organizations seeking patient input, and convene multi-stakeholder meetings to resolve complex issues that hinder patients’ access to the most advanced therapeutics.
Our two main areas of focus are:
- Streamlining the clinical trial process and making it more accessible to patients
- Ensuring biomarker testing is available to all patients diagnosed with non-small cell lung cancer
As thought leaders, we are asked to participate on a variety of committees and advisory boards to represent the interest and perspective of lung cancer patients. LUNGevity has also been actively engaged in the dialog regarding the pricing of drugs and patient values, most specifically with respect to ICER.